Cargando…

The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker)

BACKGROUND: Plasma growth differentiation factor-15 (GDF-15) biomarker levels increase in response to inflammation and tissue injury, and increased levels of GDF-15 are associated with increased risk of mortality in patients with heart failure with reduced ejection fraction (HFrEF). Sodium-glucose c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omar, Massar, Jensen, Jesper, Kistorp, Caroline, Højlund, Kurt, Videbæk, Lars, Tuxen, Christian, Larsen, Julie H., Andersen, Camilla F., Gustafsson, Finn, Køber, Lars, Schou, Morten, Møller, Jacob Eifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882292/ https://www.ncbi.nlm.nih.gov/pubmed/35219331 http://dx.doi.org/10.1186/s12933-022-01463-2

Ejemplares similares

Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)
por: Jensen, Jesper, et al.
Publicado: (2019)

Galectin-3 and fibulin-1 in systolic heart failure - relation to glucose metabolism and left ventricular contractile reserve
por: Holmager, Pernille, et al.
Publicado: (2017)

Renal dysfunction, restrictive left ventricular filling pattern and mortality risk in patients admitted with heart failure: a 7-year follow-up study
por: Schou, Morten, et al.
Publicado: (2013)

ODP154 Reduction of Cardiac Adipose Tissue Volume with Short-Term Empagliflozin in Patients with Type 2 Diabetes: Results from the SIMPLE Randomized Clinical Trial
por: Brandt-Jacobsen, Niels, et al.
Publicado: (2022)

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial
por: Jürgens, Mikkel, et al.
Publicado: (2021)

Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
por: Brandt‐Jacobsen, Niels H., et al.
Publicado: (2023)

A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
por: Jorsal, Anders, et al.
Publicado: (2014)

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years
por: Kümler, Thomas, et al.
Publicado: (2011)

Two Decades of Cardiac Amyloidosis: A Danish Nationwide Study
por: Westin, Oscar, et al.
Publicado: (2021)

Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers
por: Madelaire, Christian, et al.
Publicado: (2020)

Association between left ventricular diastolic function and right ventricular function and morphology in asymptomatic aortic stenosis
por: Christensen, Nicolaj Lyhne, et al.
Publicado: (2019)

Specialized heart failure clinics versus primary care: Extended registry-based follow-up of the NorthStar trial
por: Malmborg, Morten, et al.
Publicado: (2023)

Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study
por: Gaborit, Freja Stoltze, et al.
Publicado: (2020)

Predictors of right ventricular function as measured by tricuspid annular plane systolic excursion in heart failure
por: Kjaergaard, Jesper, et al.
Publicado: (2009)

Risk of Childhood Overweight after Exposure to Tobacco Smoking in Prenatal and Early Postnatal Life
por: Møller, Susanne Eifer, et al.
Publicado: (2014)

MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction
por: Jensen, Jesper, et al.
Publicado: (2020)

End-systolic wall stress in aortic stenosis: comparing symptomatic and asymptomatic patients
por: Carter-Storch, Rasmus, et al.
Publicado: (2019)

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study
por: Rasmussen, Jon Jarløv, et al.
Publicado: (2016)

Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure
por: Stoltze Gaborit, Freja, et al.
Publicado: (2016)

One‐Year Mortality After Intensification of Outpatient Diuretic Therapy
por: Madelaire, Christian, et al.
Publicado: (2020)

Prevalence of early stages of heart failure in an elderly risk population: the Copenhagen Heart Failure Risk Study
por: Gaborit, Freja Stoltze, et al.
Publicado: (2019)

Endogenous Testosterone Levels Are Associated with Risk of Type 2 Diabetes in Women without Established Comorbidity
por: Rasmussen, Jon J, et al.
Publicado: (2020)

GLP-1 analogues for neuroprotection after out-of-hospital cardiac arrest: study protocol for a randomized controlled trial
por: Wiberg, Sebastian, et al.
Publicado: (2016)

Comparison of systematic triage with clinical assessment in prediction of short-term mortality
por: S Iversen, Anne K, et al.
Publicado: (2015)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Association of Low-Dose Quetiapine and Diabetes
por: Højlund, Mikkel, et al.
Publicado: (2021)

Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)
por: Parveen, Saaima, et al.
Publicado: (2022)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

National all-cause mortality during the COVID-19 pandemic: a Danish registry-based study
por: Mills, Elisabeth Helen Anna, et al.
Publicado: (2020)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low‐Risk Population With Type 2 Diabetes Mellitus
por: Malmborg, Morten, et al.
Publicado: (2021)

First-in-Human Implantation of a New Transcatheter Tricuspid Valve Replacement System
por: Sondergaard, Lars, et al.
Publicado: (2023)

Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care
por: Rungby, Jorgen, et al.
Publicado: (2017)

Ethics in extracorporeal life support: a narrative review
por: Schou, Alexandra, et al.
Publicado: (2021)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Hereditary Hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis
por: Møller, Daniel V, et al.
Publicado: (2010)

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021
por: Malik, Mariam Elmegaard, et al.
Publicado: (2023)

Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
por: Lee, Matthew M.Y., et al.
Publicado: (2020)

Impella to Treat Acute Myocardial Infarct-Related Cardiogenic Shock
por: Møller, Jacob Eifer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0kqpkeqbnekmr35ecsfqkl5v6u